Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.anorl.2020.04.014 http://scihub22266oqcxt.onion/10.1016/j.anorl.2020.04.014 32482571!7198134!32482571     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Ann+Otorhinolaryngol+Head+Neck+Dis 2020 ; 137 (4): 315-317 Nephropedia Template TP {{tp|p=32482571|t=2020. Consensus statement Corticosteroid therapy in ENT in the context of the COVID-19 pandemic |pdf=|usr=}}{{32482571}} gab.com Text Consensus statement Corticosteroid therapy in ENT in the context of the COVID-19 pandemic JO: Eur Ann Otorhinolaryngol Head Neck Dis http://www.kidney.de/pget.php?&tw=1&pmid=32482571 #FOAvip This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections. Twit Text FOAVip Consensus statement Corticosteroid therapy in ENT in the context of the COVID-19 pandemic ????Eur Ann Otorhinolaryngol Head Neck Dis http://www.kidney.de/pget.php?&tw=1&pmid=32482571 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32482571 #FOAvip English Wikipedia <ref>{{Cite pmid|32482571}}</ref> Consensus statement Corticosteroid therapy in ENT in the context of the COVID-19 pandemic #MMPMID32482571 Herman P; Vincent C; Parietti Winkler C; Loundon N; Couloigner V; Tankere F; Tringali S; Gallet P; Papon JF; Montava M; Lavieille JP; Charpiot A; Schmerber S Eur Ann Otorhinolaryngol Head Neck Dis 2020[Sep]; 137 (4): 315-317 PMID32482571show ga This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections. |Adrenal Cortex Hormones/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/complications/*drug therapy[MESH] |Humans[MESH] |Otorhinolaryngologic Diseases/*drug therapy/virology[MESH] |Pandemics[MESH]Consensus statement Corticosteroid therapy in ENT in the context of t(epmc).pdf DeepDyve Pubget Overpricing